Key points are not available for this paper at this time.
Recent advances in our understanding of prostate carcinoma biology have allowed for improved risk assessments. Future development of programs to prognosticate survival by the International Union Against Cancer and the American Joint Committee on Cancer must go beyond clinical staging to incorporate risk assessment of important prognostic variables for a variety of outcomes.
Montie et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: